PREDI-LYNCH

May 1, 2025

Funding programme: Horizon Europe – EU Mission on Cancer

Call: HORIZON-MISS-2024-CANCER-01

Project coordinator: Oslo University Hospital (OUH), Norway

Partners:

University of Oslo (Norway)
Oslo Cancer Cluster (Norway)
Amsterdam UMC (Netherlands)
University College London (United Kingdom)
Karolinska Institutet (Sweden)
German Cancer Research Center – DKFZ (Germany)
Institut National de la Santé et de la Recherche Médicale – INSERM (France)
Fondazione IRCCS Istituto Nazionale dei Tumori (Italy)
Candiolo Cancer Institute – FPO-IRCCS (Italy)
University of Helsinki (Finland)
University of Graz (Austria)
University of Barcelona (Spain)
University of Minho (Portugal)
Elypta AB (Sweden)
Genos Glycoscience Research Laboratory (Croatia)
InVivo AI (Canada)
BlueSense Diagnostics (Spain)
IMMAGINA BioTechnology Srl (Italy)
NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET – NTNU (Norway)
International Agency for Research on Cancer – IARC/WHO (France)
European Organisation for Research and Treatment of Cancer – EORTC (Belgium)
Stichting Lynch Polyposis (Netherlands)
Digestive Cancers Europe – DiCE (Belgium)
European Society for Medical Oncology – ESMO (Switzerland)
The Association of European Cancer Leagues – ECL (Belgium)
International Alliance of Patients’ Organizations – IAPO (United Kingdom)
European Regional and Local Health Authorities – EUREGHA (Belgium)

Role of EUREGHA: Regional stakeholders engagement and policy support

Total budget: Total budget of €13,6 million .
EUREGHA budget: €155,625

Starting Date: May 2025 Duration: 72 months

About PREDI-LYNCH

PREDI-LYNCH (Validated Non-Invasive Liquid Biopsy Tests for Cancer Prediction in Lynch Syndrome) is a flagship Horizon Europe Mission on Cancer project aimed at revolutionising early cancer detection in individuals with Lynch Syndrome (LS) — the most common hereditary cancer predisposition syndrome. The project addresses a pressing unmet medical need: the lack of effective, minimally invasive surveillance for LS-associated cancers, including colorectal, endometrial, and urothelial cancers.

Coordinated by Oslo University Hospital, the project brings together 28 partners from 16 countries, including top academic institutions, biotech SMEs, healthcare organisations, and patient advocacy groups. Over six years (2025–2031), the consortium will develop and validate liquid biopsy-based screening methods, building towards scalable and clinically implementable early detection tools.

Goals And Objectives

The overall goal of PREDI-LYNCH is to reduce cancer burden and improve outcomes for individuals with Lynch Syndrome through early detection using non-invasive technologies.

Specific objectives include:

Develop non-invasive liquid biopsy tests for early detection of LS-related cancers.
Implement multi-omics biomarker discovery approaches supported by artificial intelligence.
Design and execute multi-national clinical trials using innovative protocols.
Establish a dedicated LS biobank as a long-term European resource.
Ensure ethical, legal, social, and economic considerations are addressed for wide adoption.
Facilitate the clinical translation and real-world scalability of novel diagnostics across EU health systems.

Work Packages and Key Activities

PREDI-LYNCH is structured into 10 work packages (WPs), each addressing a key dimension of the project:

WP1: Project Coordination and Management
WP2: Clinical Cohorts and Biobanking
WP3: Multi-omics Discovery of Early Cancer Biomarkers
WP4: Assay Development and Technical Validation
WP5: Clinical Validation and Implementation Trials
WP6: Artificial Intelligence and Predictive Modelling
WP7: Health Economic Evaluation and Ethics
WP8: Stakeholder Engagement and Dissemination
WP9: Policy and Regulatory Roadmaps
WP10: Communication and Exploitation

Our Contribution

As a partner in WP8 and WP9, EUREGHA plays a central role in ensuring the engagement of regional and local health authorities in shaping and adopting the project’s innovations. Our responsibilities include:

Coordinating regional stakeholder engagement activities across Europe.
Facilitating policy dialogues and knowledge exchange between project partners and EU/regional policymakers.
Supporting the uptake of results in regional cancer plans and early detection strategies.
Contributing to the development of policy roadmaps to enable clinical integration and sustainability.
Disseminating project insights via our broad network of European regional health authorities.

By bridging the gap between research, policy, and practice, EUREGHA contributes to ensuring that PREDI-LYNCH’s innovations are translated into real-world impact at regional level.